Laki Power Closes Financing Led By Brunnur Ventures
28.10.2019 09:00:00 EET | Business Wire | Press release
Laki Power (www.lakipower.com), a leader in real-time surveillance for high-voltage powerline infrastructure, announced today the successful closing of its first institutional investment round, led by Brunnur Ventures. The new capital will support further development of the Company’s high-voltage powerline sensor product portfolio, powered by its unique patent-pending line energy harvesting platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191027005046/en/
Inductively powered and sited directly on the phase wire, our LKX-range of sensors provides fully-autonomous, next-generation monitoring capabilities for high-voltage transmission and distribution infrastructure. (Photo: Business Wire)
“We’re pleased to announce the closing of this funding and are delighted to be working with the experienced team at Brunnur Ventures,” said Sigurjon Magnusson, CEO at Laki Power. “This round enables us to accelerate the build out of our power harvesting capabilities into an expanded range of high-value products and services that address the rapidly growing needs of power grid operators for real-time knowledge of system health and functionality.”
Electricity grids worldwide are changing, driven by the increased demands of distributed generation of wind and solar, and pressure from both customers and regulators for increased resilience, transparency and accountability.
“Addressing the need for real-time, actionable intelligence for the monitoring and management of power grid infrastructure is clearly a huge opportunity and we are seeing that utilities are deploying sensing and monitoring systems more broadly, and faster than ever before,” commented Arni Blöndal, General Partner at Brunnur Ventures.
Unique capabilities
Laki Power’s unique products are powered by the only on-market energy harvester that supports multiple sensors and communications devices with full autonomy from external power sources, eliminating the need for solar, wind or diesel generators. The Company’s PowerGRAB™ technology harvests energy from the electromagnetic field surrounding the alternating current (AC) carrying phase wires of high voltage power lines to provide direct current (DC) power for running external and internal surveillance and monitoring devices, and many other applications that need clean and stable DC power.
About Laki Power
Laki Power was founded in 2015 to transform the way line monitoring is carried out for transmission system operators (TSOs) and distribution system operators (DSOs), by bringing to market new technology that dramatically enhances the level of power that can be efficiently harvested from high voltage lines.
Electrical transmission and distribution systems worldwide span millions of kilometres. Yet despite carrying huge amounts of energy, tapping into that energy, to provide monitoring devices with power in the remote places that these lines cross, has remained a persistent challenge. Instead these systems have relied on local fossil fuel generators, wind turbines, solar cells or power from the line that requires a mini-substation to adapt voltage and power levels for proper utilization. This results in very high costs of installing, maintaining and resupplying these systems, as well as a host of other environmental, operational, logistical and maintenance issues.
Laki Power's patent pending technology can harvest up to hundred times more power than competitor solutions, offering unprecedented monitoring capacity and flexibility for a range of sensors and applications.
For more information, please visit: www.lakipower.com
About Brunnur Ventures
Brunnur Ventures is a $30m venture capital fund focused on Icelandic start-up companies, emphasizing innovation and growth, combined with scalable business models and extraordinary entrepreneurial talent.
For more information, please visit: www.brunnurventures.com
Laki Power and the Laki Power logo are registered trademarks of Laki Power in the United States and/or other countries. The names of actual companies and products mentioned herein may be the trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191027005046/en/
Contact information
Sigurjon Magnusson
CEO, Laki Power
sigurjon.magnusson@lakipower.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 17:50:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive
emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 18:12:00 EEST | Press release
emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead
Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 16:00:00 EEST | Press release
Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme
EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 16:00:00 EEST | Press release
European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea
ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 15:00:00 EEST | Press release
ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom